Overview
- In a randomized, double-blind Phase 3 study of 820 adults, VER-01 reduced pain by an average of 1.9 points versus 1.4 with placebo on a 0–10 scale over 12 weeks.
- Participants on VER-01 reported better sleep and physical function, and investigators observed no signals of dependence, misuse, dose escalation, or withdrawal.
- Adverse effects were mostly mild to moderate but led to higher discontinuation with VER-01 than placebo (17.4% vs 3.5%), with dizziness, somnolence, and nausea most common early on.
- Independent experts caution that the average advantage over placebo is small and may lack clinical relevance, while exploratory signals suggest patients with neuropathic features could benefit more and require confirmation.
- BfArM is reviewing the application for the Vertanical product, and the company indicates it expects an approval decision in the first half of 2026, with the therapy to be marketed as Exilby if authorized.